{"ticker": {"uuid": "a1d91df7-9f62-4133-981f-1cdf40d206fa", "symbol": "MAAT", "name": "MaaT Pharma SA", "exchange": "PAR", "country": "FR", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxORTFfbEc5RTJ4a0Q2RFlfN2J1NVk4Z2JKeXpveVV3eG5NQ3hTdG1wLTdVSzRsRHJicWVYXzZoTG1pM2ZJbVZaX1BzTXF3RERMVklyRjE0ZS1vU19qRHB4NTFzYzZZSnZSQUVOcTBqQndRRldkNFVCelRTQmhLcktLcnpWd1lscXFHZkNYcEphQU5WTEhxcDFvZG13T1FrRkVJbDhrMHd4cE5WU3ZWaFZVdmlDeGtEYmJab2tXQ0Z1Qi02UW4xUl9ra0hqV1kwcG4wU1FyeFBn?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T11:07:05+00:00", "published_display": "11 Jun 2026 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaaT Pharma: CHMP Likely to Issue Negative Opinion on Xervyteg", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNNnR2ZG5hV3R4a004OVR1Z19qcDc0aEREei1qei1nT3VCSzA4amhCUXV5eW9NeVlwUlUwR0JQMGxMR1laRThBRzNjVWtBcC13Qk1FSVctMVNZVkR5cmxRRUNmdTRlMDI5MGlyeUd3QTIxSHpCdGd4bURPSTV3dkhyM0tWeXBCbEVxb0s2NEtUMlpsSjdnRlNFcURLdy1jU0VHMVVQb1ZGQnBIWVRvQldWcC1XODF2M3lYUWk4Uw?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaaT Pharma: EMA's Feedback on Novel Treatment Expected Mid-2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNeTV4UEVJMjJ2ZnpIOGY4aDhEZjZqTlVZa0FVUDA3ZlNQSXcyNkhYdXczRlVWRXVuSHFWSU1GcjR1SDhlZzVscUpjelhJOUFXR1hCWTQ0ak5HenY1UzR6dTU4WFhjVFJqb3A0SUVxR1h0RXhrNC1sS2VZYUVEQ2N1enZkUEVkVjRNUC1HbkVNdmZmbmtiUUVBWG9pdDNDVnpDRGZpM1VodTViQUNneUxQV1p0OHlYSDQ5YzFnMQ?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For MaaT Pharma SA (EPA:MAAT) Before Long", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-05T07:00:00+00:00", "published_display": "05 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maat Pharma Phase III microbiome trial hits endpoints as stock soars", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQWlIybzhEN1FDRmhvNGtmb2wxZldEelpWNHpnc3hwQjZxaExiNTNhb004LTg4LVBEdWRCZ3d0VnVDWmx4RXRTOEZrZ2JNS2Y3U0lHbWFFc3FaTC1EYkxKNkhEQWtmUndSQ2pRVWtfR3BPZkZiQlloUmppaEpMUkVpLXBCNFlVSThhLS1vNDZRbDB0UFJGd1lVSWNHZXJoMk1mcENSbW1xdnpTM3laeFE?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2025-01-09T08:00:00+00:00", "published_display": "09 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaaT Pharma: Target Price Consensus and Analysts Recommendations | MAAT | FR0012634822", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNSUhSZjY4a3lROVZxZVZ2b0hnMXhaT3V0eDhSZkZnRUZBMEstY0ZzZ0M5OGhTWm5uRVJXUGZQbk04RUxtNDRGYkl2SnNQRXctOUhkanhydVQxOVcwU0Fpc3NJaEtTbEVSVGxsT1ZGS3pyWnJrYTdualJ2OFNLMENCZA?oc=5", "source_name": "marketscreener.com", "published_at": "2022-01-10T04:51:39+00:00", "published_display": "10 Jan 2022 04:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxORTFfbEc5RTJ4a0Q2RFlfN2J1NVk4Z2JKeXpveVV3eG5NQ3hTdG1wLTdVSzRsRHJicWVYXzZoTG1pM2ZJbVZaX1BzTXF3RERMVklyRjE0ZS1vU19qRHB4NTFzYzZZSnZSQUVOcTBqQndRRldkNFVCelRTQmhLcktLcnpWd1lscXFHZkNYcEphQU5WTEhxcDFvZG13T1FrRkVJbDhrMHd4cE5WU3ZWaFZVdmlDeGtEYmJab2tXQ0Z1Qi02UW4xUl9ra0hqV1kwcG4wU1FyeFBn?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T11:07:05+00:00", "published_display": "11 Jun 2026 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaaT Pharma: CHMP Likely to Issue Negative Opinion on Xervyteg", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNNnR2ZG5hV3R4a004OVR1Z19qcDc0aEREei1qei1nT3VCSzA4amhCUXV5eW9NeVlwUlUwR0JQMGxMR1laRThBRzNjVWtBcC13Qk1FSVctMVNZVkR5cmxRRUNmdTRlMDI5MGlyeUd3QTIxSHpCdGd4bURPSTV3dkhyM0tWeXBCbEVxb0s2NEtUMlpsSjdnRlNFcURLdy1jU0VHMVVQb1ZGQnBIWVRvQldWcC1XODF2M3lYUWk4Uw?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaaT Pharma: EMA's Feedback on Novel Treatment Expected Mid-2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNeTV4UEVJMjJ2ZnpIOGY4aDhEZjZqTlVZa0FVUDA3ZlNQSXcyNkhYdXczRlVWRXVuSHFWSU1GcjR1SDhlZzVscUpjelhJOUFXR1hCWTQ0ak5HenY1UzR6dTU4WFhjVFJqb3A0SUVxR1h0RXhrNC1sS2VZYUVEQ2N1enZkUEVkVjRNUC1HbkVNdmZmbmtiUUVBWG9pdDNDVnpDRGZpM1VodTViQUNneUxQV1p0OHlYSDQ5YzFnMQ?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For MaaT Pharma SA (EPA:MAAT) Before Long", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-05T07:00:00+00:00", "published_display": "05 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maat Pharma Phase III microbiome trial hits endpoints as stock soars", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQWlIybzhEN1FDRmhvNGtmb2wxZldEelpWNHpnc3hwQjZxaExiNTNhb004LTg4LVBEdWRCZ3d0VnVDWmx4RXRTOEZrZ2JNS2Y3U0lHbWFFc3FaTC1EYkxKNkhEQWtmUndSQ2pRVWtfR3BPZkZiQlloUmppaEpMUkVpLXBCNFlVSThhLS1vNDZRbDB0UFJGd1lVSWNHZXJoMk1mcENSbW1xdnpTM3laeFE?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2025-01-09T08:00:00+00:00", "published_display": "09 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaaT Pharma: Target Price Consensus and Analysts Recommendations | MAAT | FR0012634822", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNSUhSZjY4a3lROVZxZVZ2b0hnMXhaT3V0eDhSZkZnRUZBMEstY0ZzZ0M5OGhTWm5uRVJXUGZQbk04RUxtNDRGYkl2SnNQRXctOUhkanhydVQxOVcwU0Fpc3NJaEtTbEVSVGxsT1ZGS3pyWnJrYTdualJ2OFNLMENCZA?oc=5", "source_name": "marketscreener.com", "published_at": "2022-01-10T04:51:39+00:00", "published_display": "10 Jan 2022 04:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 63, "total_relevant": 6, "sentiment_summary": {"positive": 0, "negative": 1, "neutral": 5, "score": 47, "total": 6, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 2.85, "latest_week": "2026-06-19", "one_week_move": -2.9, "four_week_move": -12.3, "twelve_week_move": -56.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.217545, "market_dynamics_buy_signal": false, "relative_strength": -46.085864, "fair_value_gap": -55.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.917, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.9% over one week, -12.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Id\u00e9al Investisseur", "count": 2}, {"label": "TradingView", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "Clinical Trials Arena", "count": 1}, {"label": "marketscreener.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 5}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.9% over one week, -12.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review"}], "updated_at": "2026-06-23T03:08:19.934035+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}